Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Your search found 2 Results

  1. 1

    A World Bank vaccine commitment.

    Glennerster R; Kremer M

    [Unpublished] 2000 Apr. 11 p.

    Malaria, tuberculosis, and the strains of AIDS common in developing countries kill five million people each year. Over the last 50 years, these diseases have killed six times as many people as have died in all wars. Yet research on vaccines for these diseases remains minimal. This is in large part because R&D on vaccines is a global public good in which no one country has sufficient incentive to invest. It is also because these diseases primarily affect poor countries, and therefore potential vaccine developers believe they will be unable to sell enough vaccine at a sufficient price to recoup their research costs. World Bank president James Wolfensohn recently said that the institution plans to create a $1 billion fund to help countries purchase specified vaccines if and when they are developed. Such a fund could help ensure that there would be a market for malaria, tuberculosis, or AIDS vaccines if they were developed, and thus would create incentives for vaccine research. It could also help ensure that any vaccines developed would be affordable in poor countries. The program would be highly focused on areas of deep poverty and would be highly cost effective. (excerpt)
    Add to my documents.
  2. 2
    Peer Reviewed

    Resources required for global tuberculosis control. [Ressources nécessaires pour le contrôle de la tuberculose au niveau mondial]

    Floyd K; Blanc L; Raviglione M; Lee JW

    Science. 2002 Mar 15; 295(5562):2040-1.

    The authors estimate that to achieve the WHO's tuberculosis (TB) control targets, the 22 high-burden countries (HBCs) that collectively account for approximately 80% of the world's TB cases require about US$ 1 billion/year during the period 2001-05. A further US$ 0.2 billion/year is needed for low and lower-middle income countries outside the 22 HBCs. There is a resource gap of up to around US$ 300 million/year. Substantial progress in TB control could be achieved with increased investment that is large in the context of existing spending, but small in the wider context of global health expenditure. (author's)
    Add to my documents.